Trivant Custom Portfolio Group LLC Grows Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Trivant Custom Portfolio Group LLC boosted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 5.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,903 shares of the company’s stock after purchasing an additional 356 shares during the period. Trivant Custom Portfolio Group LLC’s holdings in Zoetis were worth $1,349,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ZTS. Webster Bank N. A. lifted its position in shares of Zoetis by 89.1% in the 1st quarter. Webster Bank N. A. now owns 174 shares of the company’s stock worth $29,000 after purchasing an additional 82 shares during the period. Neo Ivy Capital Management purchased a new position in shares of Zoetis in the 4th quarter valued at approximately $40,000. Quarry LP lifted its stake in shares of Zoetis by 273.2% in the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after purchasing an additional 153 shares during the period. LRI Investments LLC bought a new position in shares of Zoetis in the 1st quarter worth about $43,000. Finally, Ables Iannone Moore & Associates Inc. purchased a new stake in shares of Zoetis in the 4th quarter worth approximately $51,000. Institutional investors own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently commented on ZTS. Piper Sandler raised their price objective on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. Stifel Nicolaus boosted their price objective on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a report on Wednesday, September 18th. Argus upgraded Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Finally, BTIG Research boosted their price target on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $220.38.

Zoetis Stock Performance

Zoetis stock traded down $0.96 during mid-day trading on Friday, reaching $190.03. 1,697,760 shares of the stock traded hands, compared to its average volume of 2,576,563. The stock has a market capitalization of $86.09 billion, a PE ratio of 36.61, a price-to-earnings-growth ratio of 2.95 and a beta of 0.89. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.45 and a quick ratio of 2.09. The business’s 50-day moving average is $187.30 and its 200-day moving average is $175.45. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $201.92.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, topping the consensus estimate of $1.49 by $0.07. The firm had revenue of $2.36 billion for the quarter, compared to analysts’ expectations of $2.31 billion. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The business’s quarterly revenue was up 8.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.41 EPS. As a group, sell-side analysts predict that Zoetis Inc. will post 5.84 EPS for the current fiscal year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.